Aims/IntroductionWe aimed to evaluate factors that influence changes in blood low‐density lipoprotein cholesterol (LDL‐C) levels after treatment with sodium–glucose cotransporter 2 (SGLT2) inhibitors in Japanese patients with type 2 diabetes.Materials and MethodsWe retrospectively analyzed clinical data of outpatients newly initiated on SGLT2 inhibitors (n = 176) and other oral antidiabetic drugs (n = 227). The patients were classified into four subgroups according to statin administration and baseline LDL‐C levels (<120 or ≥120 mg/dL). Clinical characteristics were compared among the subgroups. Multivariate analysis was carried out to identify factors contributing to changes in LDL‐C.ResultsThe median follow‐up period was 13.0 weeks (range 11.9–14.1 weeks, min 8 weeks, maximum 16 weeks) in the SGLT2i group, and 12.0 weeks (range 10.0–14.0 weeks, min 8 weeks, maximum 16 weeks) in the control group. Both groups showed a significant decrease in LDL‐C (SGLT2i group −3.8 ± 24.7 mg/dL, control group −3.4 ± 15.0 mg/dL). Multivariate regression analyses showed that in both groups, the change in LDL‐C depended on statin use and baseline LDL‐C levels. Stratified analyses showed that LDL‐C level was significantly decreased in statin users with baseline LDL‐C ≥120 mg/dL (from 148.9 ± 33.5 to 109.3 ± 17.9 mg/dL, P = 0.002), and significantly increased in statin non‐users with baseline LDL‐C <120 mg/dL (from 96.3 ± 27.3 to 104.7 ± 24.8 mg/dL, P = 0.002). These changes were more characteristic for SGLT2 inhibitors than for other oral antidiabetic drugs (P for interaction = 0.010 and <0.001, respectively).ConclusionsLDL‐C levels and statin medication at baseline influence changes in LDL‐C after SGLT2 inhibitors treatment in Japanese patients with type 2 diabetes.

中文翻译：

---

钠-葡萄糖协同转运蛋白2抑制剂对日本2型糖尿病患者血清低密度脂蛋白胆固醇的影响

目的/简介我们的目的是评估日本 2 型糖尿病患者接受钠-葡萄糖协同转运蛋白 2 (SGLT2) 抑制剂治疗后影响血液低密度脂蛋白胆固醇 (LDL-C) 水平变化的因素。材料和方法我们回顾性分析了临床数据新开始使用 SGLT2 抑制剂的门诊患者（n= 176）和其他口服降糖药（n= 227）。根据他汀类药物给药和基线 LDL-C 水平（<120 或≥120 mg/dL），将患者分为四个亚组。比较各亚组之间的临床特征。进行多变量分析以确定导致 LDL-C 变化的因素。 结果 SGLT2i 组的中位随访期为 13.0 周（范围 11.9-14.1 周，最短 8 周，最长 16 周），而 SGLT2i 组的中位随访期为 12.0 周（范围 11.9-14.1 周，最短 8 周，最长 16 周）。对照组为 10.0–14.0 周，最短 8 周，最长 16 周。两组的 LDL-C 均显着降低（SGLT2i 组 -3.8 ± 24.7 mg/dL，对照组 -3.4 ± 15.0 mg/dL）。多变量回归分析显示，两组中 LDL-C 的变化取决于他汀类药物的使用和基线 LDL-C 水平。分层分析显示，基线 LDL-C ≥120 mg/dL 的他汀类药物使用者的 LDL-C 水平显着降低（从 148.9 ± 33.5 降至 109.3 ± 17.9 mg/dL，磷= 0.002），并且在基线 LDL-C <120 mg/dL 的非他汀类药物使用者中显着增加（从 96.3 ± 27.3 至 104.7 ± 24.8 mg/dL，磷= 0.002）。与其他口服抗糖尿病药物相比，这些变化对于 SGLT2 抑制剂来说更具特征性（磷交互作用分别 = 0.010 和 <0.001）。结论 基线时的 LDL-C 水平和他汀类药物治疗会影响日本 2 型糖尿病患者接受 SGLT2 抑制剂治疗后 LDL-C 的变化。